Sanofi, Merck vaccine to bolster vaccination rates across US
Singapore, Jan. 17 -- The US Food and Drug Administration (FDA) recently approved pharma giants Sanofi and Merck's Vaxelis, a new pediatric vaccine against six diseases. The vaccine will help to bolster vaccination rates across the US by reducing the shot burden on infants and children, according to GlobalData, a leading data and analytics company.
Vaxelis, which is indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and invasive disease due to Haemophilus influenzae type b, was developed as part of a joint-partnership between Sanofi and Merck, known as MSD outside the US and Canada.
James Mather, Pharma Analyst at GlobalData, says: "Vaxelis' approval in the US is a major regulatory br...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.